<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cholesterol</journal-id><journal-id journal-id-type="iso-abbrev">Cholesterol</journal-id><journal-id journal-id-type="publisher-id">CHOL</journal-id><journal-title-group><journal-title>Cholesterol</journal-title></journal-title-group><issn pub-type="ppub">2090-1283</issn><issn pub-type="epub">2090-1291</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23050131</article-id><article-id pub-id-type="pmc">3463157</article-id><article-id pub-id-type="doi">10.1155/2012/895326</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Improving Total-Cholesterol/HDL-Cholesterol Ratio Results in an Endothelial Dysfunction Recovery in Peripheral Artery Disease Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bleda</surname><given-names>Silvia</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>de Haro</surname><given-names>Joaqu&#x000ed;n</given-names></name></contrib><contrib contrib-type="author"><name><surname>Varela</surname><given-names>C&#x000e9;sar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Esparza</surname><given-names>Leticia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Javier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Acin</surname><given-names>Francisco</given-names></name></contrib></contrib-group><aff id="I1">Vascular Surgery and Angiology Department, Hospital Universitario Getafe, Ctra Toledo Km 12,500, 28905 Madrid, Spain</aff><author-notes><corresp id="cor1">*Silvia Bleda: <email>silbleik@yahoo.es</email></corresp><fn fn-type="other"><p>Academic Editor: Jan Wouter Jukema</p></fn></author-notes><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2012</year></pub-date><volume>2012</volume><elocation-id>895326</elocation-id><history><date date-type="received"><day>30</day><month>4</month><year>2012</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Silvia Bleda et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Aims</italic>. To evaluate the effects of variations of total-cholesterol/HDL-cholesterol ratio and the effects of the atorvastatin on endothelial function in peripheral artery disease (PAD). <italic>Material and Methods</italic>. A prospective, randomised controlled study was carried out in 150 PAD patients. Patients randomized to the control group (<italic>n</italic> = 75) were treated with antiplatelet drugs, angiotensin-converting-enzyme inhibitors and cardiovascular-risk-factor control. Experimental group (<italic>n</italic> = 75) also received treatment with atorvastatin for a month. It was determined baseline nitrite plasma levels and total-cholesterol/HDL-cholesterol ratio and after one month of treatment in both groups. It was also analysed the correlation between the gradient of nitrite levels and the differential of total-cholesterol/HDL ratio in treatment group. <italic>Results</italic>. After a month, a reduction in nitrite levels was detected in treatment group (11.88 &#x000b1; 7.8&#x02009;<italic><italic>&#x003bc;</italic></italic>M versus 5.7 &#x000b1; 1.8&#x02009;<italic><italic>&#x003bc;</italic></italic>M, <italic>P</italic> &#x0003c; 0.0001). It was shown a higher decrease in nitrite plasma levels in the atorvastatin group finding lower levels assessments (5.7 &#x000b1; 1.8&#x02009;<italic><italic>&#x003bc;</italic></italic>M versus 13.1 &#x000b1; 9.1&#x02009;<italic><italic>&#x003bc;</italic></italic>M, resp., <italic>P</italic> &#x0003c; 0.001). A significant reduction in total-cholesterol/HDL-cholesterol ratio was observed in statin group after treatment (<italic>P</italic> &#x0003c; 0.0001). A strong correlation was found between the gradient of nitrite levels and the differential of total-cholesterol/HDL-cholesterol ratio in atorvastatin group (<italic>r</italic> = 0.7; <italic>P</italic> &#x0003c; 0.001). <italic>Conclusions</italic>. Improvement of nitrite levels are associated with decreased total cholesterol/HDL ratio values in PAD patients treated with atorvastatin.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Peripheral arterial disease (PAD), the clinical manifestation of atherosclerosis in the lower limbs, is caused by a systemic chronic inflammatory state that affects the entire vascular system [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Endothelial damage plays a crucial role in the etiopathogenia of this disease [<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Endothelial dysfunction is considered to be an early event of atherosclerosis, preceding evidence of atherosclerotic plaques on angiography or ultrasound scan. Such endothelial dysfunction has been attributed to an impairment in nitric oxide (NO) bioactivity, and an increase in the formation of reactive oxygen species (ROS) [<xref rid="B4" ref-type="bibr">4</xref>]. NO has several antiatherosclerotic effects, such as inhibition of monocyte migration, inhibition of smooth muscle cell proliferation, and inhibition of platelet aggregation [<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>]. </p><p>Nitrites are the product of the oxidation of the NO derived from the endothelium. Under physiological conditions, 70%&#x02013;90% of the nitrites in plasma stem from endothelial nitric oxide synthase (eNOS) activity. Patients with PAD have been shown to have increased plasma nitrite levels from the early stages of the disease though this condition is unrelated to the severity of PAD [<xref rid="B3" ref-type="bibr">3</xref>].</p><p>In turn, hypercholesterolemia is an independent well-established risk factor for the development of atherosclerosis [<xref rid="B5" ref-type="bibr">5</xref>]. Previous studies have demonstrated that hypercholesterolemia is associated with endothelial dysfunction [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. It is known to reduce endothelial function either by decreasing the synthesis and release of endothelium-derived relaxing factors or by inactivating NO after its release from endothelial cells by its reactions with superoxide radicals [<xref rid="B9" ref-type="bibr">9</xref>]. </p><p>Meanwhile, high-density lipoprotein (HDL) has antiatherosclerotic effects, including augmentation of ability of reverse cholesterol transport, anti-inflammatory activity, inhibition of low-density lipoprotein (LDL) cholesterol oxidation, endothelial cell apoptosis, platelet aggregation, expression of cellular adhesion molecules, and re-endo-vascularization [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>].</p><p>Plasma HDL levels have been inversely related to the incidence of atherothrombotic disease [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Part of its atheroprotective effect has been associated to its role in preserving endothelial function [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. In fact, several studies have suggested that a decrease in total-cholesterol/HDL-cholesterol ratio is linked to a reduction in the risk of morbidity and mortality in cardiovascular diseases [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>].</p><p>There is some evidence that cholesterol-lowering therapy improves endothelium-dependent vasodilation in patients with normal lipid profile [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. However, there is little information regarding the effects of changes in total-cholesterol/HDL-cholesterol ratio per se on endothelium function in subjects with PAD.</p><p>The purpose of this study was to evaluate the effects of variations of total-cholesterol/HDL-cholesterol ratio on endothelial function indirectly determined by means of measurement of nitrite plasma levels in subjects with PAD. We evaluated the effects of the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitor atorvastatin on endothelial function in these subjects.</p></sec><sec id="sec2"><title>2. Material and Methods</title><p>A prospective, experimental, randomised controlled, and translational study was carried out. There were sequentially included and randomized 150 PAD patients with Fontaine stage II at the time of diagnosis, confirmed by means of haemodynamic study (Doppler) and treadmill stress tests. All the patients included have not undergone previous revascularization procedure and were not received treatment with statins or contraindications for their use. We also excluded all patients with coexistence of chronic inflammatory diseases or steroidal medication.</p><p>The target patients who met the inclusion criteria were recruited and assessed in a screening visit at the outpatient clinic of the Angiology and Vascular Surgery Department of the Getafe University Hospital. When the criteria were met, and after signing the informed consent form, the patients were randomly allocated in a 1&#x02009;:&#x02009;1 ratio to the experimental intervention arm or the control group (<xref ref-type="fig" rid="fig1">Figure 1</xref>). A computer-generated random number sequence was used for randomization. The sequence was concealed until the study arm was assigned. There were three independent vascular surgeons investigators: one who recruited and evaluated the potential target patient in the screening visit and recorded cardiovascular risk factors, treatment, and general condition at the inclusion and after a month of the inclusion, blinded to the arm to which the patients were randomized; one who generated the allocation sequence; another who enrolled participants and assigned them to one of the study groups. Patients in the control group (<italic>n</italic> = 75) were prescribed treatment with aspirin 100&#x02009;mg or clopidogrel 75&#x02009;mg daily, if aspirin intolerant, angiotensin-converting-enzyme (ACE) inhibitors, and cardiovascular-risk-factors control. All patients in the experimental group (<italic>n</italic> = 75) also received atorvastatin 40&#x02009;mg daily for a month.</p><p>Cardiovascular risk factors, treatment, and general condition were recorded on inclusion and after a month of treatment with statin. Ankle brachial index (ABI) was measured at rest as per the standard technique in the dorsalis pedis and posterior tibial arteries of both lower limbs [<xref rid="B21" ref-type="bibr">21</xref>]. Blood tests were performed at baseline and after one month of treatment with statin, which included basic clinical chemistry (glycemia, renal function, electrolytes, etc.) and lipid profile. Patients with plasma total cholesterol greater than 6.5&#x02009;mmol L<sup>&#x02212;1</sup>, LDL cholesterol greater than 3.2&#x02009;mmol L<sup>&#x02212;1</sup> or triglycerides greater than 2.25&#x02009;mmol L<sup>&#x02212;1</sup>, or those on lipid-lowering treatment were considered to have dyslipidaemia [<xref rid="B22" ref-type="bibr">22</xref>]. Patients were considered to be hypertensive if they presented with systolic blood pressure greater than 140&#x02009;mmHg and/or diastolic pressure greater than 90 mmHg and/or were on antihypertensive treatment for at least 1 year prior to inclusion in the study [<xref rid="B23" ref-type="bibr">23</xref>]. Patients were considered diabetic if they presented with baseline blood sugar greater than 120&#x02009;g dL<sup>&#x02212;1</sup> or if they required treatment with hypoglycaemics [<xref rid="B24" ref-type="bibr">24</xref>]. Chronic renal failure was defined as serum creatinine greater than 1.5&#x02009;mg dL<sup>&#x02212;1</sup> [<xref rid="B25" ref-type="bibr">25</xref>].</p><p>For the determination of plasma nitrite levels, the subjects came to the study having fasted for at least 12 hours and without having taken their usual medication during that period. Blood was drawn from an antecubital vein and centrifuged for 10 min at 800&#x02009;g, with plasma then being stored at &#x02212;4&#x000b0;C. Plasma nitrite concentrations were determined by colourimetric assay based on the Griess reaction [<xref rid="B26" ref-type="bibr">26</xref>]. This is a chemical reaction which uses sulfanilamide and N-(1-naphthyl) ethylenediamine dihydrochloride (NED) under acidic conditions (phosphoric acid). The system can detect NO<sub>2</sub>
<sup>&#x02212;</sup> in a variety of biological and experimental fluids, the limit of detection being 2.5&#x02009;mM (125&#x02009;pmol). Each sample was analysed in triplicate, taking the mean of the three determinations. The blood tests were repeated in a control group of 10 patients to assess the reproducibility of the test, the coefficient of variation being less than 5%.</p><p>Cholesterol and triglyceride levels were measured by enzymatic techniques [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>]. HDL cholesterol was measured after precipitation of apoB-containing lipoproteins with polyanions [<xref rid="B29" ref-type="bibr">29</xref>] and VLDL cholesterol after separation of VLDL (<italic>d</italic> &#x0003c; 1.006&#x02009;g &#x000b7; mL<sup>&#x02212;1</sup>) by ultracentrifugation [<xref rid="B30" ref-type="bibr">30</xref>]. The LDL cholesterol was calculated by subtracting VLDL and HDL cholesterol from total cholesterol.</p><p>The laboratory data were determined anonymously, so that the results would not be biased.</p><p>This study was approved by the Ethical Committee of Getafe University Hospital.</p><sec id="sec2.1"><title>2.1. Statistical Analysis</title><p>The sample size necessary to obtain significant differences with 80% of statistical power and an alpha error of 0.5 was calculated on the basis of previous studies which analysed NO levels in plasma in patients of similar condition [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. This sample size needed was estimated as 45 patients. Student's <italic>t</italic>-test was used for the end-points variables with normal distribution analysis and the Mann-Whitney <italic>U</italic>-test for those in which the distribution was not normal. The Kolmogorov-Smirnov and Shapiro-Wilk tests were used for the analysis of normality. The <italic>&#x003c7;</italic>
<sup>2</sup>-test was used for categorical variables and the Spearman' <italic>s</italic>-test for the correlation between continuous variables. The data were expressed as mean &#x000b1; standard deviation (SD) and the categorical as percentages. Statistical significance was assumed for <italic>P</italic> value &#x0003c;0.05.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>207 patients were consecutively assessed for inclusion in the study. Twenty-eight were excluded for not meeting inclusion criteria. Twenty-nine refused to participate, after we had explained in detail the conditions of the study and the hard recommendation of meeting the follow-up visits established per protocol. 150 patients with Fontaine stage II PAD were recruited and randomly assigned to each group, treatment (<italic>n</italic> = 75), and control (<italic>n</italic> = 75). The patient demographics features and current treatment are described in <xref ref-type="table" rid="tab1">Table 1</xref>. Thus, there were no patient dropouts during the study. All 150 patients included completed the study protocol and were analysed for the primary outcome. No major adverse reactions to the treatment with statin were recorded.</p><p>After one month of treatment with statin, a significant reduction in plasma nitrite levels was detected in treatment group patients (11.88 &#x000b1; 7.8&#x02009;<italic>&#x003bc;</italic>M versus 5.7 &#x000b1; 1.8&#x02009;<italic>&#x003bc;</italic>M, <italic>P</italic> &#x0003c; 0.0001) and in the comparison between treatment and control groups (5.7 &#x000b1; 1.8&#x02009;<italic>&#x003bc;</italic>M versus 13.1 &#x000b1; 9.1&#x02009;<italic>&#x003bc;</italic>M, resp., <italic>P</italic> &#x0003c; 0.001). No changes were found in the nitrite levels in the control group patients over the course of the study (12.5 &#x000b1; 5.1&#x02009;<italic>&#x003bc;</italic>M versus 13.1 &#x000b1; 9.1&#x02009;<italic>&#x003bc;</italic>M, <italic>P</italic> = 0.83) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>A significant reduction in plasma levels of total cholesterol, LDL cholesterol, total-cholesterol/HDL-cholesterol ratio, and total triglycerides was observed in treatment group (<xref ref-type="table" rid="tab2">Table 2</xref>).</p><p>We defined differential of total-cholesterol/HDL-cholesterol ratio in treatment group as the difference between total-cholesterol/HDL-cholesterol ratio baseline value and total-cholesterol/HDL-cholesterol ratio 1st month treatment value. As well as differential of nitrite plasma levels in treatment group as the difference between nitrite basal levels and nitrite levels after one month of treatment with atorvastatin. A strong positive Spearman's correlation was found between the differential of nitrite levels in plasma and the differential of total-cholesterol/HDL-cholesterol ratio on atorvastatin group (<italic>rs</italic> 0.7; <italic>P</italic> &#x0003c; 0.001) (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="sec4"><title>4. Discussion</title><p>The current study evaluated and analysed in vivo, the effects of the HMG-coA reductase inhibitors upon variations of NO bioavailability and variations in plasma levels of total-cholesterol/HDL-cholesterol ratio, in patients with PAD. Our data revealed that decrease in total-cholesterol/HDL-cholesterol ratio was correlated with reduction of nitrite levels in patients with PAD and atorvastatin treatment.</p><p>Hypercholesterolemia is a well-established risk factor for atherosclerosis, in particular by decreasing the availability of nitric oxide [<xref rid="B31" ref-type="bibr">31</xref>]. Oxidative stress is known to contribute to atherogenesis, and, during this process, lipid peroxidation takes place in lipoproteins as well as in arterial macrophages [<xref rid="B32" ref-type="bibr">32</xref>]. The result is a drop in the bioavailability of endothelial NO, a reduction in the effective lumen of the vessel, and an increase in sensitivity to acetylcholine-induced vasoconstriction.</p><p>Several lines of evidence indicate that HDL has beneficial antiatherosclerotic effects [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. HDL acts as a reverse cholesterol transporter by removing excess cellular cholesterol to the liver, resulting in protection against atherosclerosis. This is the predominant antiatherosclerotic effect of HDL. However, HDL has multifactorial effects to protect vascular function. Thus, HDL activates endothelial NO synthase by enhancing Akt and MAP kinases leading to an increase in NO, suppresses endothelial cell apoptosis by activation of the Akt pathway and inhibition of caspase 3 and 9, inhibits the oxidation of LDLs, limits inflammation processes, stimulates prostacyclin production, and upregulates cyclooxygenase-2 expression leading to anticoagulation and vasodilation [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Therefore, under a low HDL cholesterol condition, atherosclerotic processes develop progressively, resulting in cardiovascular impairment.</p><p>Previous studies related to the effects of atorvastatin therapy on lipid profile and oxidative stress revealed that atorvastatin therapy decreased the levels of oxidative stress [<xref rid="B35" ref-type="bibr">33</xref>]. An improvement on endothelial function has been described in patients diagnosed of PAD treated with atorvastatin at the beginning of the treatment. Nevertheless, this effect was not maintained at long term [<xref rid="B36" ref-type="bibr">34</xref>]. Different mechanisms by which atorvastatin improves endothelial function have been postulated. It is well known that statins augment endothelium-dependent vasodilation through an increase in NO bioavailability and decrease in oxidative stress and inflammation [<xref rid="B37" ref-type="bibr">35</xref>, <xref rid="B38" ref-type="bibr">36</xref>]. In the present study, we have observed that four-week treatment with the HMG-CoA reductase inhibitor atorvastatin in patients with PAD decreased total-cholesterol/HDL-cholesterol ratio, and this is associated with the improvement on endothelial function provoked at the beginning of the statin treatment. According the results of this study, it could be hypothesized that a possible mechanism by which atorvastatin improves endothelial function is by its decreasing Total-cholesterol/HDL-cholesterol ratio effect. </p><p>Nevertheless, recent studies have shown that atorvastatin has more beneficial effects on endothelial function than other statins at similar lipid reduction [<xref rid="B39" ref-type="bibr">37</xref>]. However, the conclusions from other studies remain inconsistent [<xref rid="B40" ref-type="bibr">38</xref>] contributing to certain controversy.</p><p>Anyway, Sugiura et al. have previously described an inverse correlation between total-cholesterol/HDL-cholesterol ratio and endothelial function by flow-mediated dilatation [<xref rid="B41" ref-type="bibr">39</xref>]. Our data support their results through variations of nitrite plasma levels. In addition, these findings underline the importance of plasma total-cholesterol/HDL-cholesterol values as a risk factor of endothelial dysfunction in PAD patients. It is noteworthy that the correlation between nitrite levels and total-cholesterol/HDL-cholesterol found in the current study was mainly determined by increasing levels of HDL after atorvastatin treatment.</p><p>The limitations of this study include the fact that nitrite levels are influenced by endogenous and exogenous factors such as dietary nitrates, the inhalation of atmospheric NO, its formation in the salivary glands, and renal function. Although it is not possible to exclude these factors, these data are in line with observations from earlier studies. While dealing with plasma nitrites and not other nitrates may seem to be a limitation, it is known that over 70%&#x02013;90% of all plasma nitrites originate from eNOS activity [<xref rid="B42" ref-type="bibr">40</xref>].</p></sec><sec id="sec5"><title>5. Conclusions</title><p>The present study demonstrated that improvement of nitrite plasma levels, a marker of endothelial function, is associated with decreased total cholesterol/HDL ratio values in patients with PAD treated with atorvastatin. In the early stages of PAD, the impact of total-cholesterol/HDL-cholesterol ratio may relate to endothelial damage.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Atherosclerosis&#x02014;an inflammatory disease</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1999</year><volume>340</volume><issue>2</issue><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="other">2-s2.0-0033552883</pub-id><pub-id pub-id-type="pmid">9887164</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Haro</surname><given-names>J</given-names></name><name><surname>Ac&#x000ed;n</surname><given-names>F</given-names></name><name><surname>L&#x000f3;pez-Quintana</surname><given-names>A</given-names></name><etal/></person-group><article-title>Direct assotiation between C-reactive protein serum levels and endothelial dysfunction in patients with claudication</article-title><source><italic>European Journal of Vascular and Endovascular Surgery</italic></source><year>2008</year><volume>35</volume><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">18077193</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Haro</surname><given-names>J</given-names></name><name><surname>Mart&#x000ed;nez-Aguilar</surname><given-names>E</given-names></name><name><surname>Florez</surname><given-names>A</given-names></name><name><surname>Varela</surname><given-names>C</given-names></name><name><surname>Bleda</surname><given-names>S</given-names></name><name><surname>Acin</surname><given-names>F</given-names></name></person-group><article-title>Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs</article-title><source><italic>Interactive Cardiovascular and Thoracic Surgery</italic></source><year>2009</year><volume>9</volume><issue>1</issue><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="other">2-s2.0-67650156439</pub-id><pub-id pub-id-type="pmid">19376804</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Cirino</surname><given-names>G</given-names></name><name><surname>Casini</surname><given-names>A</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name></person-group><article-title>Nitric oxide as a signaling molecule in the vascular system: an overview</article-title><source><italic>Journal of Cardiovascular Pharmacology</italic></source><year>1999</year><volume>34</volume><issue>6</issue><fpage>879</fpage><lpage>886</lpage><pub-id pub-id-type="other">2-s2.0-0032707717</pub-id><pub-id pub-id-type="pmid">10598133</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zulli</surname><given-names>A</given-names></name><name><surname>Hare</surname><given-names>DL</given-names></name><name><surname>Buxton</surname><given-names>BF</given-names></name><name><surname>Black</surname><given-names>MJ</given-names></name></person-group><article-title>High dietary methionine plus cholesterol exacerbates atherosclerosis formation in the left main coronary artery of rabbits</article-title><source><italic>Atherosclerosis</italic></source><year>2004</year><volume>176</volume><issue>1</issue><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="other">2-s2.0-4043155719</pub-id><pub-id pub-id-type="pmid">15306178</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Cooke</surname><given-names>JP</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>1990</year><volume>86</volume><issue>1</issue><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="other">2-s2.0-0025307354</pub-id><pub-id pub-id-type="pmid">2195060</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>MJ</given-names></name><name><surname>Kharbanda</surname><given-names>RK</given-names></name><name><surname>Cross</surname><given-names>J</given-names></name><etal/></person-group><article-title>Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia</article-title><source><italic>Circulation Research</italic></source><year>2001</year><volume>88</volume><issue>2</issue><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="other">2-s2.0-0035793340</pub-id><pub-id pub-id-type="pmid">11157665</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Saurbier</surname><given-names>B</given-names></name><name><surname>Just</surname><given-names>H</given-names></name></person-group><article-title>Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>1993</year><volume>92</volume><issue>2</issue><fpage>652</fpage><lpage>662</lpage><pub-id pub-id-type="other">2-s2.0-0027249912</pub-id><pub-id pub-id-type="pmid">8349804</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;ger</surname><given-names>RH</given-names></name></person-group><article-title>Association of asymmetric dimethylarginine and endothelial dysfunction</article-title><source><italic>Clinical Chemistry and Laboratory Medicine</italic></source><year>2003</year><volume>41</volume><issue>11</issue><fpage>1467</fpage><lpage>1472</lpage><pub-id pub-id-type="other">2-s2.0-0344306684</pub-id><pub-id pub-id-type="pmid">14656027</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansell</surname><given-names>BJ</given-names></name><name><surname>Watson</surname><given-names>KE</given-names></name><name><surname>Fogelman</surname><given-names>AM</given-names></name><name><surname>Navab</surname><given-names>M</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name></person-group><article-title>High-density lipoprotein function: recent advances</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2005</year><volume>46</volume><issue>10</issue><fpage>1792</fpage><lpage>1798</lpage><pub-id pub-id-type="other">2-s2.0-27644587961</pub-id><pub-id pub-id-type="pmid">16286161</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davignon</surname><given-names>J</given-names></name></person-group><article-title>Beneficial cardiovascular pleiotropic effects of statins</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>23</issue><supplement>supplement 1</supplement><fpage>III39</fpage><lpage>III43</lpage><pub-id pub-id-type="other">2-s2.0-2942720515</pub-id><pub-id pub-id-type="pmid">15198965</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DJ</given-names></name><name><surname>Rifkind</surname><given-names>BM</given-names></name></person-group><article-title>High-density lipoprotein&#x02014;the clinical implications of recent studies</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1989</year><volume>321</volume><issue>19</issue><fpage>1311</fpage><lpage>1316</lpage><pub-id pub-id-type="other">2-s2.0-0024449985</pub-id><pub-id pub-id-type="pmid">2677733</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names></name></person-group><article-title>HDL cholesterol and protective factors in atherosclerosis</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>23</issue><supplement>supplement 1</supplement><fpage>III8</fpage><lpage>III14</lpage><pub-id pub-id-type="other">2-s2.0-2942750054</pub-id><pub-id pub-id-type="pmid">15198960</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XP</given-names></name><name><surname>Zhao</surname><given-names>SP</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>QC</given-names></name></person-group><article-title>Protective effect of high density lipoprotein on endothelium-dependent vasodilatation</article-title><source><italic>International Journal of Cardiology</italic></source><year>2000</year><volume>73</volume><issue>3</issue><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="other">2-s2.0-0034737948</pub-id><pub-id pub-id-type="pmid">10841964</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuvin</surname><given-names>JT</given-names></name><name><surname>Patel</surname><given-names>AR</given-names></name><name><surname>Sidhu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relation between high-density lipoprotein cholesterol and peripheral vasomotor function</article-title><source><italic>American Journal of Cardiology</italic></source><year>2003</year><volume>92</volume><issue>3</issue><fpage>275</fpage><lpage>279</lpage><pub-id pub-id-type="other">2-s2.0-0042848537</pub-id><pub-id pub-id-type="pmid">12888130</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Cairns</surname><given-names>R</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Prognostic utility of ApoB/AI, total cholesterol/HDL, Non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes results from PROVE IT-TIMI 22</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2009</year><volume>29</volume><issue>3</issue><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="other">2-s2.0-61549120401</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keil</surname><given-names>U</given-names></name><name><surname>Liese</surname><given-names>AD</given-names></name><name><surname>Hense</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany</article-title><source><italic>European Heart Journal</italic></source><year>1998</year><volume>19</volume><issue>8</issue><fpage>1197</fpage><lpage>1207</lpage><pub-id pub-id-type="other">2-s2.0-0032147051</pub-id><pub-id pub-id-type="pmid">9740341</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Real</surname><given-names>JT</given-names></name><name><surname>Chaves</surname><given-names>FJ</given-names></name><name><surname>Mart&#x000ed;nez-Us&#x000f3;</surname><given-names>I</given-names></name><name><surname>Garc&#x000ed;a-Garc&#x000ed;a</surname><given-names>AB</given-names></name><name><surname>Ascaso</surname><given-names>JF</given-names></name><name><surname>Carmena</surname><given-names>R</given-names></name></person-group><article-title>Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia</article-title><source><italic>European Heart Journal</italic></source><year>2001</year><volume>22</volume><issue>6</issue><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="other">2-s2.0-0034931412</pub-id><pub-id pub-id-type="pmid">11237541</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myoishi</surname><given-names>M</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Minamino</surname><given-names>T</given-names></name><etal/></person-group><article-title>Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome</article-title><source><italic>Circulation</italic></source><year>2007</year><volume>116</volume><issue>11</issue><fpage>1226</fpage><lpage>1233</lpage><pub-id pub-id-type="other">2-s2.0-34948866189</pub-id><pub-id pub-id-type="pmid">17709641</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Silver</surname><given-names>DL</given-names></name><name><surname>Costet</surname><given-names>P</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name></person-group><article-title>Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><issue>42</issue><fpage>33053</fpage><lpage>33058</lpage><pub-id pub-id-type="other">2-s2.0-0034693064</pub-id><pub-id pub-id-type="pmid">10918065</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Shemanski</surname><given-names>L</given-names></name><name><surname>Manolio</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health study</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>1999</year><volume>19</volume><issue>3</issue><fpage>538</fpage><lpage>545</lpage><pub-id pub-id-type="other">2-s2.0-0033012553</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="other"><collab>National Heart, Lung, and Blood Institute</collab><article-title>Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III, or ATPIII)</article-title><comment>2006, <ext-link ext-link-type="uri" xlink:href="http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.htm">http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.htm</ext-link></comment></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdecchia</surname><given-names>P</given-names></name><name><surname>Angeli</surname><given-names>F</given-names></name></person-group><article-title>The seventh report of the joint national committee on the prevention, detection, evaluation and treatment of high blood pressure: the weapons are ready</article-title><source><italic>Revista Espanola de Cardiologia</italic></source><year>2003</year><volume>56</volume><issue>9</issue><fpage>843</fpage><lpage>847</lpage><pub-id pub-id-type="other">2-s2.0-0242440925</pub-id><pub-id pub-id-type="pmid">14519269</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><collab>Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</collab><article-title>Report of the expert committee on the diagnosis and classification of diabetes mellitus</article-title><source><italic>Diabetes Care</italic></source><year>2001</year><volume>24</volume><issue>supplement 1</issue><fpage>5</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11194240</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>R</given-names></name><name><surname>Hern&#x000e1;ndez Jara</surname><given-names>J</given-names></name></person-group><article-title>Chronic renal insufficiency. I: definition, clinical course stages, progression mechanisms, etiology, and diagnostic criteria</article-title><source><italic>Nefrologia</italic></source><year>2001</year><volume>21</volume><fpage>18</fpage><lpage>20</lpage><pub-id pub-id-type="other">2-s2.0-2242463066</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name><name><surname>Dejam</surname><given-names>A</given-names></name><name><surname>Kerber</surname><given-names>S</given-names></name><name><surname>Kelm</surname><given-names>M</given-names></name></person-group><article-title>Griess method for nitrite measurement of aqueous and protein-containing samples</article-title><source><italic>Methods in Enzymology</italic></source><year>2002</year><volume>359</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="other">2-s2.0-0036437091</pub-id><pub-id pub-id-type="pmid">12481568</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allain</surname><given-names>CC</given-names></name><name><surname>Poon</surname><given-names>LS</given-names></name><name><surname>Chan</surname><given-names>CSG</given-names></name></person-group><article-title>Enzymatic determination of total serum cholesterol</article-title><source><italic>Clinical Chemistry</italic></source><year>1974</year><volume>20</volume><issue>4</issue><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="other">2-s2.0-0016373654</pub-id><pub-id pub-id-type="pmid">4818200</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Welle</surname><given-names>HF</given-names></name><name><surname>Baartscheer</surname><given-names>T</given-names></name><name><surname>Fiolet</surname><given-names>JW</given-names></name></person-group><article-title>Influence of free glycerol on enzymic evaluation of triglycerides</article-title><source><italic>Clinical Chemistry</italic></source><year>1984</year><volume>30</volume><issue>6</issue><fpage>1102</fpage><lpage>1103</lpage><pub-id pub-id-type="other">2-s2.0-0021448003</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>M</given-names></name><name><surname>Scholnick</surname><given-names>HR</given-names></name><name><surname>Morfin</surname><given-names>R</given-names></name></person-group><article-title>Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions</article-title><source><italic>Journal of Lipid Research</italic></source><year>1970</year><volume>11</volume><issue>6</issue><fpage>583</fpage><lpage>595</lpage><pub-id pub-id-type="other">2-s2.0-0014876627</pub-id><pub-id pub-id-type="pmid">4100998</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havel</surname><given-names>RJ</given-names></name><name><surname>Eder</surname><given-names>HJ</given-names></name><name><surname>Bragdon</surname><given-names>JH</given-names></name></person-group><article-title>The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum</article-title><source><italic>The Journal of clinical investigation</italic></source><year>1955</year><volume>34</volume><issue>9</issue><fpage>1345</fpage><lpage>1353</lpage><pub-id pub-id-type="other">2-s2.0-33745026603</pub-id><pub-id pub-id-type="pmid">13252080</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmusen</surname><given-names>C</given-names></name><name><surname>Cynober</surname><given-names>L</given-names></name><name><surname>Couderc</surname><given-names>R</given-names></name></person-group><article-title>Arginine and statins: relationship between the nitric oxide pathway and the atherosclerosis development</article-title><source><italic>Annales de Biologie Clinique</italic></source><year>2005</year><volume>63</volume><issue>5</issue><fpage>443</fpage><lpage>455</lpage><pub-id pub-id-type="other">2-s2.0-30744435355</pub-id><pub-id pub-id-type="pmid">16230278</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblat</surname><given-names>M</given-names></name><name><surname>Hayek</surname><given-names>T</given-names></name><name><surname>Hussein</surname><given-names>K</given-names></name><name><surname>Aviram</surname><given-names>M</given-names></name></person-group><article-title>Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2004</year><volume>24</volume><issue>1</issue><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="other">2-s2.0-0347753257</pub-id></element-citation></ref><ref id="B35"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harangi</surname><given-names>M</given-names></name><name><surname>Seres</surname><given-names>I</given-names></name><name><surname>Varga</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage</article-title><source><italic>European Journal of Clinical Pharmacology</italic></source><year>2004</year><volume>60</volume><issue>10</issue><fpage>685</fpage><lpage>691</lpage><pub-id pub-id-type="other">2-s2.0-12444339797</pub-id><pub-id pub-id-type="pmid">15490140</pub-id></element-citation></ref><ref id="B36"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleda</surname><given-names>S</given-names></name><name><surname>de Haro</surname><given-names>J</given-names></name><name><surname>Florez</surname><given-names>A</given-names></name><name><surname>Varela</surname><given-names>C</given-names></name><name><surname>Esparza</surname><given-names>L</given-names></name><name><surname>Acin</surname><given-names>F</given-names></name></person-group><article-title>Long-term pleiotropic effect of statins upon nitric oxide and C-reactive protein levels in patients with peripheral arterial disease</article-title><source><italic>Heart Asia</italic></source><year>2011</year><volume>3</volume><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">27326011</pub-id></element-citation></ref><ref id="B37"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kureishi</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Shiojima</surname><given-names>I</given-names></name><etal/></person-group><article-title>The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals</article-title><source><italic>Nature Medicine</italic></source><year>2000</year><volume>6</volume><issue>9</issue><fpage>1004</fpage><lpage>1010</lpage><pub-id pub-id-type="other">2-s2.0-0033826581</pub-id></element-citation></ref><ref id="B38"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rikitake</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Rho GTPases, statins, and nitric oxide</article-title><source><italic>Circulation Research</italic></source><year>2005</year><volume>97</volume><issue>12</issue><fpage>1232</fpage><lpage>1235</lpage><pub-id pub-id-type="other">2-s2.0-33644694919</pub-id><pub-id pub-id-type="pmid">16339495</pub-id></element-citation></ref><ref id="B39"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reriani</surname><given-names>MK</given-names></name><name><surname>Dunlay</surname><given-names>SM</given-names></name><name><surname>Gupta</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials</article-title><source><italic>European Journal of Cardiovascular Prevention and Rehabilitation</italic></source><year>2011</year><volume>18</volume><issue>5</issue><fpage>704</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">21450596</pub-id></element-citation></ref><ref id="B40"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murrow</surname><given-names>JR</given-names></name><name><surname>Sher</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><etal/></person-group><article-title>The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin</article-title><source><italic>Journal of Clinical Lipidology</italic></source><year>2012</year><volume>6</volume><issue>1</issue><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">22264573</pub-id></element-citation></ref><ref id="B41"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>T</given-names></name><name><surname>Dohi</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of lipid profile and high blood pressure on endothelial damage</article-title><source><italic>Journal of Clinical Lipidology</italic></source><year>2011</year><volume>5</volume><issue>6</issue><fpage>460</fpage><lpage>466</lpage><pub-id pub-id-type="other">2-s2.0-79960467022</pub-id><pub-id pub-id-type="pmid">22108149</pub-id></element-citation></ref><ref id="B42"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Dejam</surname><given-names>A</given-names></name><name><surname>Lauer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals</article-title><source><italic>Free Radical Biology and Medicine</italic></source><year>2003</year><volume>35</volume><issue>7</issue><fpage>790</fpage><lpage>796</lpage><pub-id pub-id-type="other">2-s2.0-10744229717</pub-id><pub-id pub-id-type="pmid">14583343</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Method of randomization and allocation concealment.</p></caption><graphic xlink:href="CHOL2012-895326.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Comparison of plasma nitrite levels (<italic>&#x003bc;</italic>M) at baseline and after a month of atorvastatin therapy (*<italic>P</italic> &#x0003c; 0.05 on comparison baseline versus a month treatment). There were no statistical differences between the control group data.</p></caption><graphic xlink:href="CHOL2012-895326.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p> Positive Spearman's correlation between differential total cholesterol/HDL ratio and differential nitrite plasma levels in treatment group (<italic>r</italic> = 0.7, <italic>P</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="CHOL2012-895326.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic data and treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Treatment group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic>
</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> (75) (%)</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic> (75) (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">71.4&#x02009;&#x000b1;&#x02009;10.8</td><td align="center" rowspan="1" colspan="1">70.51&#x02009;&#x000b1;&#x02009;9.7</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">65 (87)</td><td align="center" rowspan="1" colspan="1">62 (82.6)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">55 (73.3)</td><td align="center" rowspan="1" colspan="1">57 (76)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">DM</td><td align="center" rowspan="1" colspan="1">30 (40)</td><td align="center" rowspan="1" colspan="1">33 (44)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking</td><td align="center" rowspan="1" colspan="1">41 (55)</td><td align="center" rowspan="1" colspan="1">39 (52)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex smoker</td><td align="center" rowspan="1" colspan="1">26 (35)</td><td align="center" rowspan="1" colspan="1">32 (42.6)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">AMI</td><td align="center" rowspan="1" colspan="1">10 (14)</td><td align="center" rowspan="1" colspan="1">8 (10.6)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidaemia</td><td align="center" rowspan="1" colspan="1">18 (25)</td><td align="center" rowspan="1" colspan="1">12 (16)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">CVA</td><td align="center" rowspan="1" colspan="1">5 (6.6)</td><td align="center" rowspan="1" colspan="1">6 (8)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Antiplatelet treatment</td><td align="center" rowspan="1" colspan="1">65 (86.6)</td><td align="center" rowspan="1" colspan="1">69 (92)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE inhibitors</td><td align="center" rowspan="1" colspan="1">35 (46.7)</td><td align="center" rowspan="1" colspan="1">30 (40)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">ARA-II</td><td align="center" rowspan="1" colspan="1">10 (13.3)</td><td align="center" rowspan="1" colspan="1">8 (10.6)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">B-blocker</td><td align="center" rowspan="1" colspan="1">11 (14.6)</td><td align="center" rowspan="1" colspan="1">12 (16)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitrites</td><td align="center" rowspan="1" colspan="1">5 (6.7)</td><td align="center" rowspan="1" colspan="1">3 (4)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr><tr><td align="left" rowspan="1" colspan="1">CA antagonists</td><td align="center" rowspan="1" colspan="1">15 (20)</td><td align="center" rowspan="1" colspan="1">17 (22.6)</td><td align="center" rowspan="1" colspan="1">n.s</td></tr></tbody></table><table-wrap-foot><fn><p>DM: diabetes mellitus; AMI: acute myocardial infarction; CVA: cerebrovascular accident.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Initial lipid-profile values and values after 1 month of treatment with atorvastatin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Mean&#x02009;&#x000b1;&#x02009;DS</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total CHOL baseline</td><td align="center" rowspan="1" colspan="1">5.4&#x02009;&#x000b1;&#x02009;1.3&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td><td align="center" rowspan="2" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total CHOL after treatment</td><td align="center" rowspan="1" colspan="1">3.8&#x02009;&#x000b1;&#x02009;0.1&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDL-CHOL baseline </td><td align="center" rowspan="1" colspan="1">3.4&#x02009;&#x000b1;&#x02009;1.&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td><td align="center" rowspan="2" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-CHOL after treatment</td><td align="center" rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.6&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HDL-CHOL baseline </td><td align="center" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.3&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td><td align="center" rowspan="2" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-CHOL after treatment</td><td align="center" rowspan="1" colspan="1">1.4&#x02009;&#x000b1;&#x02009;0.4&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CHOL/HDL baseline </td><td align="center" rowspan="1" colspan="1">4&#x02009;&#x000b1;&#x02009;0.9&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td><td align="center" rowspan="2" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">CHOL/HDL after treatment</td><td align="center" rowspan="1" colspan="1">2.7&#x02009;&#x000b1;&#x02009;0.6&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TGC baseline </td><td align="center" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.5&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td><td align="center" rowspan="2" colspan="1">0.024</td></tr><tr><td align="left" rowspan="1" colspan="1">TGC after treatment</td><td align="center" rowspan="1" colspan="1">1.1&#x02009;&#x000b1;&#x02009;0.4&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TGC/HDL baseline </td><td align="center" rowspan="1" colspan="1">2.3&#x02009;&#x000b1;&#x02009;1.3&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td><td align="center" rowspan="2" colspan="1">0.113</td></tr><tr><td align="left" rowspan="1" colspan="1">TGC/HDL after treatment</td><td align="center" rowspan="1" colspan="1">2&#x02009;&#x000b1;&#x02009;1.2&#x02009;mmol&#x02009;L<sup>&#x02212;1</sup>
</td></tr></tbody></table></table-wrap></floats-group></article>